TY - JOUR T1 - Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis JF - medRxiv DO - 10.1101/2020.07.13.20151340 SP - 2020.07.13.20151340 AU - A. I. Mourad AU - R. Gniadecki Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/15/2020.07.13.20151340.abstract N2 - Background Drug survival studies have been utilized to evaluate the real-world effectiveness of biologics used in psoriasis. However, the increasing volume of drug survival data suffers from large variability due to regional differences in drug availability, patient selection and biologic reimbursement.Objectives To conduct a meta-analysis of biologic drug survival to determine comparative effectiveness of the biologics in a real-world setting.Methods Studies reporting drug survival for biologic therapy in psoriasis were identified by a systematic literature search. Hazard ratio data for drug discontinuation were estimated directly from published Kaplan-Meier estimator curves at year 1, 2 and 5 of treatment and compared pairwise for the following biologics: ustekinumab, adalimumab, etanercept, infliximab, secukinumab and ixekizumab. This pooled hazard ratios were used to estimate 2- and 5-year overall drug survival rates.Results Ustekinumab had the longest persistence at 2 years and 5 years among all biologics included in this meta-analysis. Adalimumab was superior to etanercept and infliximab at 5 years. Pooled 5-year drug survival rates for adalimumab, etanercept, and infliximab were 46.3%, 35.9% and 34.7%, respectively. 2- and 5-year data were not available for anti-IL-17 drugs, but at 1-year ustekinumab outperformed secukinumab, the latter being equal to anti-TNFs.Conclusions Ustekinumab is characterized by longer drug survival than TNF inhibitors and IL-17 inhibitors. Estimated pooled 2- and 5-year drug survival rates may serve as a useful tool for patient communication and clinical decision-making.Competing Interest StatementDr. Gniadecki has received speakers honorarium from Mallinckrodt, Janssen, AbbVie, Novartis, and Leo Pharma, is on the advisory board for Mallinckrodt, Janssen, Amgen, AbbVie, Eli Lily, Sanofi, Novartis, and Leo Pharma. Dr. Gniadecki is an investigator in clinical trials for Janssen, Celgene, AbbVie, and Leo Pharma. Dr. Mourad has no conflicts of interest to declare.Funding StatementThe study was supported by the Canadian Institutes of Health Research (CIHR) and the Canadian Association of Psoriasis Patients in the form of a research student studentship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStatistical used to run the meta-analysis is published in Mendeley. Mourad, Ahmed; Gniadecki, Robert (2020), Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis, Mendeley Data, V1, doi: 10.17632/jb2dz98yn7.1 http://dx.doi.org/10.17632/jb2dz98yn7.1 ER -